SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
WALTHAM, Mass., Aug. 14, 2017 -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced it has filed a Form 15 with the Securities and Exchange Commission completing the process of delisting and deregistering its securities under the Exchange Act.
The Company announced on July 25, 2017, that it would begin the process of delisting and deregistering its securities and filed a Form 25 on August 4, 2017 as part of the process.
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include our proprietary cardiovascular test to guide treatment of high risk patients; our proprietary ILUSTRA Inflammation Management Program; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Contact: Eric Collins 617-886-6045
